Focus: Viatris China is a generics and small-molecule manufacturer headquartered in Shanghai, operating as a public company focused on established brands across multiple therapeutic areas.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Hot — 132 jobs added in 30d
Net +42 (132 new, 90 removed). Aggressive expansion phase.
Best suited for commercial, regulatory, and operations professionals seeking stable generics execution; unattractive for scientists pursuing innovation or long-term R&D growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product representing 27% of revenue; established COPD franchise with sustained Part D utilization.
Help build intelligence for Viatris (2)
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Viatris (2)'s SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver facing material patent cliff in 4 years; extended-release formulation at risk of generic displacement.
Established pain franchise approaching loss of exclusivity with limited pipeline support for replacement.
Post-LOE generic with sustained psychiatric market share; mature cash generator.
Multi-indication corticosteroid franchise with approaching exclusivity cliff.
Legacy statin franchise with mature market penetration and competitive generic landscape.
300 discontinued, 291 duplicate formulations not shown
+42 more products with revenue data
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
+219 more products
Recent restructuring activity suggests financial pressure; evaluate internal stability and severance implications before committing to multi-year tenure.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo